|Bid||0.00 x 1300|
|Ask||0.00 x 1100|
|Day's Range||23.09 - 24.87|
|52 Week Range||17.60 - 106.30|
|Beta (3Y Monthly)||1.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.00|
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that in connection with the appointment of Maximo F. Nougues as Puma’s Chief Financial Officer, the Compensation Committee of Puma’s Board of Directors approved a grant to Mr. Nougues of an inducement stock option to purchase 90,000 shares of Puma common stock, at an exercise price per share equal to the closing price of Puma’s common stock on the grant date. The option was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2018 San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that results from the subgroup of patients with hormone receptor positive breast cancer from the Company’s Phase III ExteNET Trial of neratinib for early stage HER2-Amplified breast cancer are being presented at the 2018 San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.
Puma Biotechnology, Inc. , a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas.
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30. Clovis Oncology’s stock price grew from $11.63 at the close of business on October 31 to $17.21 at the close of the market on November 30, which reflects ~48% growth in November.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on December 2, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 44,875 shares of Puma common stock to 10 new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma.
On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%. On November 8, Portola Pharmaceuticals stock price closed at $23.14, which was ~21.41% growth from its previous close of $19.06. On November 7, Portola Pharmaceuticals stock price closed at $19.06, which was ~2.80% growth from its previous close of $18.54. On November 7, the company hit its 52-week low of $18.18.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:10 a.m.
HENDERSON, NV / ACCESSWIRE / November 7, 2018 / Midterm elections are expected to result in a split Congress, which should increase predictability for the biotech industry, and prevent, what some see as disruptive, government dictated pricing, less likely than if there is a Congress controlled by one party. Propanc Biopharma, Inc. (PPCB) is one biotech firm you should look at today. The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer.
In a press release on July 31, Puma Biotechnology (PBYI) announced that Health Canada would review the company’s New Drug Submission for NERLYNX in the extended adjuvant setting for early-stage HER2-positive breast cancer after Herceptin-based adjuvant therapy.
Puma Biotechnology (PBYI) reported net sales of $52.6 million for NERLYNX in the third quarter, which is higher than its revenues of $50.8 million reported in the second quarter. According to the company’s third-quarter earnings conference call, Puma Biotechnology has attributed the growth to an increase in the number of patients being prescribed NERLYNX and patients choosing to stay on the therapy.
According to Puma Biotechnology’s (PBYI) third-quarter earnings conference call, the company expects NERLYNX’s net product revenues to be $175 million–$200 million for 2018. The company has provided a conservative guidance range—assuming that there might be lower patient starts in November and December due to the holidays.
On November 1, Puma Biotechnology (PBYI) closed at $20.07, which was 48.01% lower than its previous closing price. The stock has fallen 78.34% from $92.65 on January 2 to $20.07 on November 2. Puma Biotechnology stock rose 13.90% compared to its previous closing price and closed at $22.86 on November 5.
Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.
Shares of Puma Biotechnology Inc. plummeted 38% toward a 2 1/2-year low, to pace all premarket decliners, after the company reported third-quarter earnings and revenue that beat expectations, but reported disappointing results of its key product, the breast cancer treatment Nerlynx. That prompted J.P. Morgan to swing to bearish from bullish and slash its stock price target. Total revenue rose to $62.6 million from $6.1 million a year ago, topping the FactSet consensus of $57.9 million, but Nerlynx sales of $52.6 million was below expectations of $58.1 million. The company said late Thursday on the post-earnings conference call with analysts that the percentage of patients who discontinued the use of Nerlynx because of adverse events increased to about 18%. J.P. Morgan's Cory Kasimov downgraded Puma to underweight from overweight and cut his price target to $23 from $83. "There simply doesn't appear to be enough new patient starts to offset the discontinuations and patients rolling off [Nerlynx] therapy after 12 months," Kasimov wrote in a note to clients. the stock had already tumbled 61% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 1.2% and the S&P 500 had tacked on 2.5%.
Puma Biotech (PBYI) delivered earnings and revenue surprises of 65.42% and 13.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Los Angeles-based company said it had a loss of 37 cents. The biopharmaceutical company posted revenue of $62.6 million in the period. Puma Biotech shares have dropped 61 percent ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2018. Unless otherwise stated, all comparisons are for the third quarter 2018 compared to the third quarter 2017.
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 1, 2018 following release of its third quarter 2018 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.